Novavax announced a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™, its recombinant protein-based, non-mRNA COVID-19...
Roughly six decades after the first attempt to develop a vaccine for respiratory syncytial virus, the Food and Drug Administration is poised to approve several shots by next winter. No RSV vaccine has ever been approved...